Cognitive Decline in Non-demented PD

Completed · Phase 4 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).

Key facts

Study ID

NCT01340885

Run by

Oregon Health and Science University

People needed

9

Starts

2011-01-01

Expected to finish

2013-01-01

Last updated by the study team

2020-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Parkinson's disease
• Respond to levodopa therapy

You may not qualify if…

• Dementia
• Psychiatric disorders including anxiety disorders, dissociative disorders, mood disorders, schizophrenia and related disorders, or ADD/ADHD
• Any clinically unstable disease such as cancer, HIV/AIDS, heart condition, liver disease, kidney or renal failure or others that might require hospitalization
• Evidence for another neurological disease (history of seizures, Alzheimer disease, multiple sclerosis or other movement disorders);
• Currently using any of the study drugs;
• Colorblindness

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.